- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04913922
Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML (AARON)
An Open-Label Phase II Study of Relatlimab (BMS-986016) With Nivolumab (BMS-936558) in Combination With 5-Azacytidine for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older Acute Myeloid Leukemia Patients
The clinical trial will test the safety and tolerability of a combination therapy (azacitidine in combination with two checkpoint inhibitors, nivolumab [Anti-PD1] and relatlimab [Anti-LAG3]) in patients with relapsed/refractory Acute Myeloid Leukemia (AML) and patients ≥ 65 years with initial diagnosis of AML.
Primary objectives are:
- maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the combination therapy during the lead-in phase of the clinical trial (6-12 patients) and
- objective response rate (ORR) of the combination therapy in the phase II part of the study (up to 24 patients).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Marion Subklewe, MD
- Phone Number: +498944000
- Email: marion.subklewe@med.uni-muenchen.de
Study Contact Backup
- Name: Veit Bücklein, MD
- Phone Number: +498944000
- Email: veit.buecklein@med.uni-muenchen.de
Study Locations
-
-
-
Munich, Germany, 81377
- Recruiting
- University Hospital, LMU Munich
-
Contact:
- Marion Subklewe, MD
- Phone Number: +49-894400-0
- Email: marion.subklewe@med.uni-muenchen.de
-
Contact:
- Veit Bücklein, MD
- Phone Number: +49-89-4400-0
- Email: veit.buecklein@med.uni-muenchen.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Cohort 1 (R/R AML):
- Patients with AML who have failed first line induction chemotherapy (consisting of a minimum of two intensive chemotherapy cycles, e.g. 7+3 or HAM) or patients with AML who have relapsed after achieving complete remission (CR), CRi, or CRp, or patients who have failed up to one prior salvage therapy
Cohort 2 (frontline older AML):
- Patients aged ≥65 years with previously untreated AML who are unfit for or decline standard induction therapy.
General inclusion criteria:
- Patients not eligible for intensive induction chemotherapy and/or allogeneic stem cell transplant.
- Age ≥18 years
- ECOG Performance Status ≤2
- Adequate organ function:
Total bilirubin ≤2 x ULN (≤3 × ULN if due to leukemic involvement or Gilbert's syndrome) AST and ALT ≤2.5 × ULN (≤5.0 × ULN if due to leukemic involvement) Serum creatinine ≤2 × ULN or glomerular filtration rate (GFR) ≥50 mL/h
- Adequate cardiac function: TTE with documented LVEF ≥50%
- At least 2 weeks OR at least 5 half-lives interval from prior treatment to time of initiation of study medication
- GvHD of grade ≤A on ≤10 mg prednisone without any additional immunosuppressive therapies (tacrolimus, ciclosporin, etc.)
- Written informed consent
- Negative pregnancy test and adequate methods of contraception for females of childbearing potential, adequate methods of contraception for males
Exclusion Criteria:
- Acute promyelocytic leukemia (APL)
- Biphenotypic or bilineage leukemia
- Known allergy or hypersensitivity to 5-azacytidine, nivolumab, relatlimab, or any of their components
- History of life-threatening toxicity related to prior immune therapy
- Previous treatment with immunotherapeutic drugs targeting PD-1/PD-L1 in combination with 5-azacytidine
- Previous treatment with LAG-3 targeted agents
- Known history of severe interstitial lung disease or severe pneumonitis
- Known history (active, known, or suspected) of any of the following autoimmune diseases:
inflammatory bowel disease rheumatoid arthritis systemic progressive sclerosis systemic lupus erythematosus autoimmune vasculitis
- Active uncontrolled pneumonitis
- Active uncontrolled infection
- Symptomatic or poorly controlled CNS leukemia
- Confirmed history of encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent
- Uncontrolled or significant cardiovascular disease
- Troponin T (TnT) or I (TnI) > 2 × institutional ULN
- Organ allografts
- Allogeneic hematopoietic stem cell transplantation within the last 100 days before first study drug administration
- Active GvHD > grade A
- Known human immunodeficiency virus seropositivity
- Known positivity for hepatitis B by surface antigen expression or active hepatitis C infection
- Other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety
- Patients unwilling or unable to comply with the protocol
- Patients who are pregnant or breastfeeding
- Prisoners and subjects who are compulsory detained
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Combination therapy
5-azacitidine 75 mg/m2 body surface area s.c. for 7 days nivolumab 480mg i.v. day 1 relatlimab 80-160mg i.v. day 1 repeat day 28 |
s.c. 75 mg/m2 BSA for 7 days
480 mg i.v.
80-160mg i.v.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose (MTD)
Time Frame: after completion of the first cycle in the fist 6-12 patients, approximately during the first 6-12 months of study conduct
|
To determine the MTD of relatlimab in combination with nivolumab and 5-azacytidine in patients with R/R AML.
|
after completion of the first cycle in the fist 6-12 patients, approximately during the first 6-12 months of study conduct
|
Dose-limiting toxicities (DLTs)
Time Frame: after completion of the first cycle in the fist 6-12 patients, approximately during the first 6-12 months of study conduct
|
To determine the DLT of relatlimab in combination with nivolumab and 5-azacytidine in patients with R/R AML.
|
after completion of the first cycle in the fist 6-12 patients, approximately during the first 6-12 months of study conduct
|
Objective response rate (ORR)
Time Frame: During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct
|
To estimate the ORR to treatment with relatlimab + nivolumab + 5-azacytidine in patients with R/R AML and Patients ≥65 years with initial diagnosis of AML
|
During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hematologic improvement
Time Frame: During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct
|
To determine the number of patients with R/R AML or Patients ≥65 years with initial diagnosis of AML treated with relatlimab + nivolumab + 5-azacytidine who have a hematologic improvement (HI) in platelets, hemoglobin, or absolute neutrophil count (ANC)
|
During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct
|
Blast reduction
Time Frame: During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct
|
To determine the number of patients with R/R AML or Patients ≥65 years with initial diagnosis of AML treated with relatlimab + nivolumab + 5-azacytidine who have a blast reduction (defined as ≥50% reduction in blast percentage compared to baseline blast percentage in bone marrow)
|
During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct
|
Duration of response (DOR)
Time Frame: During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct
|
To assess the duration of response (DOR) of patients with R/R AML or Patients ≥65 years with initial diagnosis of AML treated with relatlimab + nivolumab + 5-azacytidine.
|
During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct
|
Disease-free survival (DFS)
Time Frame: During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct
|
To assess the disease-free survival (DFS) of patients with R/R AML or Patients ≥65 years with initial diagnosis of AML treated with relatlimab + nivolumab + 5-azacytidine.
|
During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct
|
Overall survival (OS)
Time Frame: During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct
|
To assess the overall survival (OS) of patients with R/R AML or Patients ≥65 years with initial diagnosis of AML treated with relatlimab + nivolumab + 5-azacytidine.
|
During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunological changes
Time Frame: During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct
|
To study immunological changes in the peripheral blood and bone marrow in response to relatlimab + nivolumab + 5-azacytidine therapy, assessed by the frequency of T-cell (subsets), regulatory T cells, and immune checkpoint expression on blasts and T cells by flow cytometry and RNA Sequencing
|
During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct
|
Molecular changes
Time Frame: During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct
|
To study the methylation status of blast DNA in the peripheral blood and bone marrow in response to relatlimab + nivolumab + 5-azacytidine therapy
|
During Phase II expansion phase, after completion of lead-in phase, approximately during months 7-48 of study conduct
|
Collaborators and Investigators
Investigators
- Principal Investigator: Marion Subklewe, MD, Department of Medicine III, University of Munich
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
- Azacitidine
Other Study ID Numbers
- CA224-065
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on Azacitidine Injection
-
Nanexa ABUppsala UniversityCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)Sweden
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingAcute Myeloid Leukemia | Myelodysplastic SyndromesChina
-
Grupo Cooperativo de Estudio y Tratamiento de las...Celgene Corporation; Germans Trias i Pujol Hospital; Hospital Son LlatzerUnknown
-
Bioniche Pharma USA LLCCompletedMyelodysplastic SyndromeUnited States, France
-
Wuhan Union Hospital, ChinaNot yet recruitingMyelodysplastic Syndromes
-
Centre Leon BerardNETRIS PharmaRecruitingAcute Myeloid Leukemia RefractoryFrance
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRecurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic SyndromesChina
-
Johns Hopkins All Children's HospitalRecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Juvenile Myelomonocytic Leukemia | Mixed Phenotype Acute LeukemiaUnited States
-
The First Affiliated Hospital of Soochow UniversityRecruitingB Acute Lymphoblastic Leukemia | High Risk Acute Lymphoblastic Leukemia | Ph-Negative ALLChina
-
Andrew DinardoBristol-Myers SquibbWithdrawn